title: The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients.
abstract: OBJECTIVE
  To investigate the possible association between the Osteopontin (OPN) gene polymorphisms and the susceptibility and chemotherapy response of acute myeloid leukemia patients.
  
  
  METHODS
  A total of 381 patients with de nova AML and 430 healthy controls were enrolled. All patients received Ara-C-based standard induction chemotherapy regimens, and the treatment response was evaluated. Several polymorphisms in the human OPN encoding gene have been identified. The OPN) gene polymorphisms at 3 loci, namely, -156 GG>G, -443 C>T and -66T>G were determined.
  
  
  RESULTS
  We identified that the -443C>T polymorphism was the only one which is closely related to AML. Compared with the -443TT carriers, our data showed that the -443CC genotype carriers were significantly related to a higher risk for AML. The -443CC genotype was also more prevalent in poor response groups than in good response group. The -443CC carriers are more likely to have poor response to AML treatment. Cellular assay indicated that the leukemic cell lines receiving the OPN -443C transfection have a significantly lower apoptosis rate to Ara-C treatment compared to cell lines transfected with -443T.
  
  
  CONCLUSIONS
  The findings of this study suggest OPN-443C>T gene polymorphism may be sued as a molecular for susceptibility and chemotherapy response of AML.
authors.affiliation: Department of Hematology, Shengjing Hospital of China Medical University, Shengjing City, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Yang
authors.forename: Ying Chun
authors.initials: YC
authors.lastname: Li
authors.forename: Guo Jun
authors.initials: GJ
authors.lastname: Zhang
authors.forename: Kun
authors.initials: K
authors.lastname: Yao
authors.forename: Rong
authors.initials: R
authors.lastname: Hu
authors.forename: Bin
authors.initials: B
authors.lastname: Wu
mesh_terms: D000328:Adult; D000483:Alleles; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D017209:Apoptosis; D045744:Cell Line, Tumor; D002681:China; D003561:Cytarabine / Q000627:therapeutic use; D004198:Disease Susceptibility; D005260:Female; D005838:Genotype; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D014162:Transfection
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D053495:Osteopontin